An open non-randomized phase IV trial examining interfering cross-reactivity in serological diagnostics of flavivirus infections in Swedish travelers following vaccination with the live dengue vaccine Qdenga

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-520655-92-00

Acronym

The DenVacc Study

Enrollment

Registered

2025-05-14

Start date

2025-09-11

Completion date

Unknown

Last updated

2025-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

No medical condition, prophylactic vaccine against dengue fever

Brief summary

IgG antibody levels in serum against TBEV, YFV, ZIKV and JE at day 90 after two doses of Qdenga compared to before vaccination

Interventions

DRUGQdenga powder and solvent for solution for injection Dengue tetravalent vaccine (live

DRUGattenuated)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
IgG antibody levels in serum against TBEV, YFV, ZIKV and JE at day 90 after two doses of Qdenga compared to before vaccination	—

Countries

Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026